Why the study?
Reduced phosphorylation of cMyBP-C is linked to compromised contractility in heart failure patients, but the effects of modulating its dephosphorylation state remained to be determined.
Do cMyBP-C peptides 302A and 302S improve cardiac contractility in ex-vivo experimental heart failure models?
Population
Papillary muscle fibers and myofibrils from cMyBP-C AAA mice, NTG mice, MI rats, and sham rats
Comparison
cMyBP-C peptides 302A and 302S vs controls across disease and non-disease models
Design
Preclinical in vitro experimental study
Authors
Loading...
Hypothesis-generating for cMyBP-C peptides in HF; requires validation before any clinical consideration.
Do cMyBP-C peptides 302A and 302S improve cardiac contractility in ex-vivo experimental heart failure models?
cMyBP-C peptides 302A and 302S improve sarcomere contractility and relaxation in ex-vivo models of heart failure, suggesting a potential therapeutic target.
Hou et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: